{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:14:47Z","timestamp":1790309687449,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Short-term treatment for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B remains unsatisfactory. The aim of our study was to compare the efficacy and safety of two sequential regimens of pegylated interferon (PEG-IFN)-\u03b1 and telbivudine (LdT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with biopsy-proven HBeAg-negative chronic hepatitis B, elevated alanine aminotransferase (ALT) and serum HBV DNA\u22652,000 IU\/ml were randomized 1:1 at baseline to receive PEG-IFN 180 \u03bcg\/week for 24 weeks followed by LdT 600 mg\/day for 24 weeks (PEG-IFN first), or vice versa (LdT first), plus 24-week follow-up; individuals with HCV, HDV or HIV coinfections and lamivudine resistance were excluded. Primary end points were serum HBV DNA&lt;2,000 IU\/ml and normal ALT at week 72.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 30 patients (86% male, median age 48 years) were enrolled: mean \u00b1sdbaseline serum HBV DNA was 5.56 \u00b11.4 log IU\/ml and ALT was 2.9 \u00b12.5x upper limit of normal. At end of follow-up (week 72), HBV DNA&lt;2,000 IU\/ml was achieved in 13.3% of participants in the PEG-IFN first group versus 46.7% of those in the LdT first group ( P=0.046). Mean \u00b1sdALT levels were significantly lower in the LdT first group (1.3 \u00b10.9 versus 3.2 \u00b12.7x upper limit of normal; P=0.03). PEG-IFN dose was reduced in 2 (7%) patients and 1 (7%) patient dropped out due to myalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sequential treatment with 24 weeks PEG-IFN followed or preceded by 24 weeks of LdT is safe. Virological response rate at week 72 was significantly higher in patients treated with LdT followed by PEG-IFN than vice versa. A sequential antiviral regimen of LdT followed by PEG-IFN, if confirmed in larger series, could improve response rates compared with standard PEG-IFN monotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2281","type":"journal-article","created":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T10:28:21Z","timestamp":1344335301000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["A Randomized Controlled Trial of Sequential Pegylated Interferon-\u03b1 and Telbivudine or\n                    <i>Vice Versa<\/i>\n                    for 48 Weeks in Hepatitis B E Antigen-Negative Chronic Hepatitis B"],"prefix":"10.1177","volume":"18","author":[{"given":"Paola","family":"Piccolo","sequence":"first","affiliation":[{"name":"Hepatology Unit, Tor Vergata University, Rome, Italy"},{"name":"Medicine Unit, Fatebenefratelli Hospital Isola Tiberina, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lenci","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Tor Vergata University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"di Paolo","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Tor Vergata University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Demelia","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Cagliari University Hospital, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Sorbello","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Cagliari University Hospital, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Nosotti","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Cagliari University Hospital, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Angelico","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Tor Vergata University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,1,1]]},"reference":[{"key":"bibr1-IMP2281","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-37583"},{"key":"bibr2-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00315-8"},{"key":"bibr3-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)00384-7"},{"key":"bibr4-IMP2281","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200411003-00008"},{"key":"bibr5-IMP2281","volume-title":"Introduction of hepatitis B vaccine into childhood immunization services.","author":"World Health Organization.","year":"2001"},{"key":"bibr6-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(00)80830-0"},{"key":"bibr7-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.11.002"},{"key":"bibr8-IMP2281","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckp168"},{"key":"bibr9-IMP2281","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21643"},{"key":"bibr10-IMP2281","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20616"},{"key":"bibr11-IMP2281","first-page":"43","volume":"52","author":"Enomoto M.","year":"2006","journal-title":"Clin Lab"},{"key":"bibr12-IMP2281","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.060327"},{"key":"bibr13-IMP2281","first-page":"42","volume":"22","author":"Brunetto M.R.","year":"1995","journal-title":"J Hepatol"},{"key":"bibr14-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00266-5"},{"key":"bibr15-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"bibr16-IMP2281","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"bibr17-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2008.03.011"},{"key":"bibr18-IMP2281","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.17915"},{"key":"bibr19-IMP2281","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042957"},{"key":"bibr20-IMP2281","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"bibr21-IMP2281","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"bibr22-IMP2281","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02490.x"},{"key":"bibr23-IMP2281","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"bibr24-IMP2281","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1466"},{"key":"bibr25-IMP2281","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01006.x"},{"key":"bibr26-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.06.002"},{"key":"bibr27-IMP2281","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01332.x"},{"key":"bibr28-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.019"},{"key":"bibr29-IMP2281","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23722"},{"key":"bibr30-IMP2281","doi-asserted-by":"publisher","DOI":"10.1309\/42D6-W7PL-FX0A-LBXF"},{"key":"bibr31-IMP2281","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.04.008"},{"key":"bibr32-IMP2281","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23905"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:51:05Z","timestamp":1777380665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.3851\/IMP2281"],"URL":"https:\/\/doi.org\/10.3851\/imp2281","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}